Thierry Mauvernay

Mr. Mauvernay is the president of Debiopharm, a Swiss, privately owned biopharmaceutical company founded by his father over 40 years ago. With 15 ongoing drug research programs, Debiopharm has developed two therapies for cancer patients, oxaliplatin and triptorelin, and a potential 3rd head & neck cancer drug currently in phase III development with an international partner. Mr. Mauvernay aspires to bring curative drug therapies and visionary health care solutions to patients worldwide.